Valuation Boston Scientific Corporation
Stocks
BSX
US1011371077
Advanced Medical Equipment & Technology
|
Market Closed -
NYSE
16:00:02 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 45.69 USD | -0.70% |
|
+2.93% | -52.08% |
| 10-22 | Laboratory operator Quest reports cyber breach affecting patient records | RE |
| 10-21 | Abbott cuts 2026 sales growth view, plans to spin off nutrition business | RE |
Company Valuation: Boston Scientific Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 60,534 | 66,273 | 84,691 | 131,642 | 141,351 | 66,215 | - | - |
| Change | - | 9.48% | 27.79% | 55.44% | 7.37% | -53.16% | - | - |
| Enterprise Value (EV) 1 | 67,674 | 74,280 | 92,928 | 141,974 | 150,822 | 72,626 | 71,710 | 68,345 |
| Change | - | 9.76% | 25.1% | 52.78% | 6.23% | -51.85% | -1.26% | -4.69% |
| P/E | 61.6x | 103x | 54x | 71.5x | 49.1x | 17.3x | 18.1x | 16.5x |
| PBR | 3.64x | 3.77x | 4.39x | 6.05x | 5.84x | 2.43x | 2.18x | 1.98x |
| PEG | - | -3x | 0x | 4.3x | 0.9x | 0.5x | -4.08x | 1.6x |
| Capitalization / Revenue | 5.09x | 5.23x | 5.95x | 7.86x | 7.04x | 3.13x | 2.99x | 2.82x |
| EV / Revenue | 5.69x | 5.86x | 6.53x | 8.48x | 7.51x | 3.44x | 3.24x | 2.91x |
| EV / EBITDA | 16.5x | 20.8x | 22.6x | 29.3x | 25.3x | 11.2x | 10.7x | 9.4x |
| EV / EBIT | 22.5x | 22.9x | 24.9x | 31.3x | 26.9x | 12.4x | 11.8x | 10.3x |
| EV / FCF | 51.4x | 79.2x | 51.9x | 53.7x | 41.2x | 19.2x | 19.4x | 14.9x |
| FCF Yield | 1.94% | 1.26% | 1.93% | 1.86% | 2.43% | 5.22% | 5.16% | 6.72% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.69 | 0.45 | 1.07 | 1.25 | 1.94 | 2.634 | 2.518 | 2.773 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 11,888 | 12,682 | 14,240 | 16,747 | 20,074 | 21,126 | 22,136 | 23,511 |
| EBITDA 1 | 4,103 | 3,574 | 4,106 | 4,839 | 5,973 | 6,495 | 6,675 | 7,274 |
| EBIT 1 | 3,010 | 3,241 | 3,738 | 4,529 | 5,612 | 5,845 | 6,098 | 6,620 |
| Net income 1 | 985 | 642 | 1,570 | 1,853 | 2,898 | 3,753 | 3,676 | 4,189 |
| Net Debt 1 | 7,140 | 8,007 | 8,237 | 10,332 | 9,471 | 6,410 | 5,495 | 2,130 |
| Reference price 2 | 42.48 | 46.27 | 57.81 | 89.32 | 95.35 | 45.69 | 45.69 | 45.69 |
| Nbr of stocks (in thousands) | 1,424,992 | 1,432,311 | 1,464,983 | 1,473,827 | 1,482,442 | 1,449,230 | - | - |
| Announcement Date | 2/2/22 | 2/1/23 | 1/31/24 | 2/5/25 | 2/4/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 17.34x | 3.44x | 11.18x | -.--% | 66.22B | ||
| 34.53x | 5.85x | 22.47x | 0.28% | 249B | ||
| 36.99x | 6.96x | 21.81x | 0.63% | 162B | ||
| 51.68x | 12.65x | 27.12x | -.--% | 157B | ||
| 49.46x | 12.26x | 27.02x | -.--% | 52.3B | ||
| 20.5x | 2.46x | 12.41x | 2.46% | 52.18B | ||
| 35.31x | 7.06x | 22.39x | -.--% | 51.34B | ||
| 33.72x | 6.68x | 22.73x | 0.59% | 48.79B | ||
| 79.42x | 7.56x | 22.95x | -.--% | 44.57B | ||
| 54.47x | 8.79x | 31.27x | -.--% | 40.68B | ||
| Average | 41.34x | 7.37x | 22.14x | 0.4% | 92.42B | |
| Weighted average by Cap. | 39.74x | 7.52x | 22.44x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BSX Stock
- Valuation Boston Scientific Corporation
Select your edition
All financial news and data tailored to specific country editions
















